Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Seroquel XR Monotherapy in Major Depressive Disorder (AMBER)
NCT00351169Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- May 2006
- Countries
- 9
01
Overview
Phase 3, randomised, double-blind trial of quetiapine in major depressive disorder (MDD), sponsored by AstraZeneca. Primary endpoint: Montgomery-Asberg Depression Rating Scale at 8 weeks. Started May 2006; status: completed.
02
Drugs
quetiapine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT00351169.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00351169.